Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cefotaxime
Drug ID BADD_D00390
Description Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).
Indications and Usage Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery.
Marketing Status approved
ATC Code J01DD01
DrugBank ID DB00493
KEGG ID D07647
MeSH ID D002439
PubChem ID 5742673
TTD Drug ID D0D1HA
NDC Product Code 0143-9933; 0143-9931; 0143-9935; 0143-9930
UNII N2GI8B1GK7
Synonyms Cefotaxime | Cephotaxim | Cefotaxim | Biosint | Cefotaxime Sodium | Sodium, Cefotaxime | Cefradil | Taporin | Fotexina | HR-756 | HR 756 | HR756 | Kendrick | Ru-24756 | Ru 24756 | Ru24756 | Benaxima | Claforan | Primafen | Klaforan
Chemical Information
Molecular Formula C16H17N5O7S2
CAS Registry Number 63527-52-6
SMILES CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agranulocytosis01.02.03.0010.000146%Not Available
Alanine aminotransferase increased13.03.04.005--
Anaemia01.03.02.0010.000097%
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock24.06.02.004; 10.01.07.0020.000146%Not Available
Angina pectoris24.04.04.002; 02.02.02.0020.000073%
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Aplastic anaemia01.03.03.002--Not Available
Arrhythmia02.03.02.0010.000073%Not Available
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.0010.000073%Not Available
Blood lactate dehydrogenase increased13.04.02.002--
Body temperature increased13.15.01.001--Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Chills15.05.03.016; 08.01.09.0010.000049%
Cholestasis09.01.01.0010.000073%Not Available
Colitis07.08.01.001--
Condition aggravated08.01.03.0040.000049%Not Available
Cyanosis23.06.04.005; 02.11.04.004; 24.03.01.007; 22.02.02.0070.000049%
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.000146%
Drug hypersensitivity10.01.01.0010.000190%Not Available
Drug interaction08.06.03.0010.000122%Not Available
Encephalopathy17.13.02.001--
Enterocolitis07.08.03.003--
Eosinophilia01.02.04.0010.000122%
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene